Literature DB >> 19669274

Antiviral therapy in patients with chronic hepatitis B and hepatocellular carcinoma: post-thermal ablation. Better late than never?

Eugene R Schiff1.   

Abstract

Entities:  

Year:  2007        PMID： 19669274      PMCID： PMC2716875          DOI： 10.1007/s12072-007-9036-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  7 in total

1.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Hideo Yoshida; Haruhiko Yoshida; Eriko Goto; Takahisa Sato; Takamasa Ohki; Ryota Masuzaki; Ryosuke Tateishi; Tadashi Goto; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Hepatol Int       Date:  2007-09-26       Impact factor: 6.047

3.  Lamivudine as initial treatment for chronic hepatitis B in the United States.

Authors:  J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

4.  Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw.

Authors:  A Tsubota; Y Arase; F Ren; H Tanaka; K Ikeda; H Kumada
Journal:  J Med Virol       Date:  2001-10       Impact factor: 2.327

5.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Histological outcome during long-term lamivudine therapy.

Authors:  Jules L Dienstag; Robert D Goldin; E Jenny Heathcote; H W L Hann; Mary Woessner; Sally L Stephenson; Stephen Gardner; D Fraser Gray; Eugene R Schiff
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

7.  Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

Authors:  H L-Y Chan; A Y Hui; M L Wong; A M-L Tse; L C-T Hung; V W-S Wong; J J-Y Sung
Journal:  Gut       Date:  2004-10       Impact factor: 23.059
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.